Curis, Inc.

Good morning, ladies and gentlemen, and welcome to the Curie's third quarter 2024 business update call. At this time, all lines are in a listen-only mode. Following the presentation, we will conduct a question and answer session. If at any time during this call, you require immediate assistance, please press star zero for the operator. This call is being recorded on Thursday, November 14, 2024. I would now like to turn the conference over over to Diantha Naval, QRIS Chief Financial Officer. Please go ahead.

Thank you, and welcome to QRIS's third quarter 2024 business update call. Before we begin, I would like to encourage everyone to go to the investor section of our website at www.qris.com to find our third quarter 2024 business update press release and related financial tables. I would also like to remind everyone that during the call, we will be making forward-looking statements which are based upon our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and actual results may differ materially. For additional details, please see our SEC filings. Joining me on today's call are Jim Denser, President and Chief Executive Officer, and Jonathan Zung, Chief Development Officer. We will also be available for a question and answer period at the end of the call. I'd now like to turn the call over to Jim.

Thank you, Dantha. Good morning, everyone, and welcome to QRIS's third quarter business update call. Let's start with our take-aim lymphoma study, which is evaluating emavucirtib in combination with ibrutinib in relapsed refractory PCNSL patients that have failed after treatment with the BTK inhibitor. These patients are generally treated with a methotrexate-based regimen, which includes chemo or radiation in the frontline setting. followed by a BTK inhibitor when a patient's disease progresses. It's when this treatment fails in the salvage line setting that patients become eligible to enroll in our study and receive M of Usertib in combination with ibrutinib. The thesis for this combination, which is supported by both preclinical data and our early clinical data, is that blocking both of the pathways driving NHL, blocking the TLR pathway with emavucirtib and blocking the BCR pathway with ibrutinib, can enable patients to achieve an objective response even after they've progressed on ibrutinib. In September, at the third annual IRAC IV Symposium in Cancer, we released an update of our PCNSL data with 10 evaluable patients. These data showed three complete responses, CRs, one unconfirmed complete response, CRU, and two partial responses, or PRs. The duration of response for three of the four patients with a CR or CRU was greater than six months. These data are very early but also encouraging, especially given the high unmet need in this population. We continue to enroll patients in this study. and are actively engaging with regulatory authorities to gain alignment on the registrational path. As a reminder, this study is being run in the US, Europe, and Israel. It goes without saying that defining the registrational path to approval is a critical next step in MFUSRTIB's development, and I'm pleased with the progress we're making. Now let's move on to our Take Aim Leukemia study, which is evaluating MFUSRTIB as monotherapy in patients with relapsed refractory AML. At ASCO and EHA earlier this year, we provided updated data for patients with a FLT3 mutation. These data showed six of 11 evaluable patients achieved an objective response, including three CRs, one CRH, and two MLFSs. Also of note, three of the 11 patients were naive to treatment with a FLT3 inhibitor. all three of these patients achieved an objective response. And three of the remaining eight patients, those who had failed prior treatment with a FLT3 inhibitor, achieved an objective response. At the ASH meeting next month, an expanded data set of 19 response-available patients will be presented by Dr. Eric Weiner from Dana-Farber in an oral presentation on Monday, December 9th. We will also be providing updated data for our study in patients with high-risk MDS in a poster by lead author Dr. Guillermo Garcia-Monero from MD Anderson being presented on Sunday, December 8th. Overall, I'm very pleased with the progress in both our Take Aim leukemia and Take Aim lymphoma studies, and I look forward to providing additional updates as the year progresses. With that, I'll turn the call over to Diantha for the financial update. Diantha?